Additional file 1 of TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro

Additional file 1: Table S1-S11. Table S1. Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomization (STROBE-MR) checklist. Table S2. The details of eQTL used in the study. Table S3. Primers used in qPCR experiments. Table S4. Mendelian Randomization Analysis Results for Blood Gene Expression and ALS Outcomes of SNPs under different criteria. Table S5. Mendelian Randomization Analysis Results for Brain Gene Expression and ALS Outcomes of SNPs under different criteria. Table S6. Mendelian Randomization Analysis Results for Spinal cord Gene Expression and ALS Outcomes of SNPs under different criteria. Table S7. Druggable genes associated with ALS. Table S8. Sensitivity analyses by MR-Egger and weighted median methods. Table S9. The results of colocalization analysis. Table S10. Wald ratio approach supporting the expression of druggable genes significantly associated with ALS risk. Table S11. The phenome-wide MR results of blood TBK1 in IVW or Wald ratio method.

附加文件1：表S1~S11。表S1：加强版孟德尔随机化流行病学观察性研究报告规范（STROBE-MR）检查表。表S2：本研究所用表达数量性状位点（expression quantitative trait locus, eQTL）的详细信息。表S3：定量聚合酶链反应（quantitative polymerase chain reaction, qPCR）实验所用引物。表S4：不同筛选标准下单核苷酸多态性（single nucleotide polymorphism, SNP）对应血液基因表达与肌萎缩侧索硬化（amyotrophic lateral sclerosis, ALS）转归的孟德尔随机化分析结果。表S5：不同筛选标准下SNP对应大脑基因表达与ALS转归的孟德尔随机化分析结果。表S6：不同筛选标准下SNP对应脊髓基因表达与ALS转归的孟德尔随机化分析结果。表S7：与ALS相关的可成药基因。表S8：采用MR-Egger法与加权中位数法开展的敏感性分析结果。表S9：共定位分析结果。表S10：Wald比值法验证的与ALS风险显著相关的可成药基因表达分析结果。表S11：采用逆方差加权（inverse variance weighted, IVW）法或Wald比值法对血液TBK1开展的全表型组孟德尔随机化分析结果。